Waverly Advisors LLC Buys 211,009 Shares of Humacyte, Inc. (NASDAQ:HUMA)

Waverly Advisors LLC lifted its holdings in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 331.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 274,579 shares of the company's stock after purchasing an additional 211,009 shares during the quarter. Waverly Advisors LLC owned 0.22% of Humacyte worth $1,387,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Woodline Partners LP boosted its position in shares of Humacyte by 235.7% during the 4th quarter. Woodline Partners LP now owns 2,848,802 shares of the company's stock worth $14,386,000 after acquiring an additional 2,000,268 shares in the last quarter. Squarepoint Ops LLC bought a new position in shares of Humacyte during the fourth quarter valued at $132,000. ProShare Advisors LLC raised its stake in shares of Humacyte by 30.4% during the fourth quarter. ProShare Advisors LLC now owns 30,852 shares of the company's stock valued at $156,000 after acquiring an additional 7,188 shares during the last quarter. Deutsche Bank AG raised its stake in shares of Humacyte by 50.8% during the fourth quarter. Deutsche Bank AG now owns 78,474 shares of the company's stock valued at $396,000 after acquiring an additional 26,419 shares during the last quarter. Finally, Crestline Management LP bought a new position in shares of Humacyte during the fourth quarter valued at $66,000. 44.71% of the stock is owned by institutional investors.

Analysts Set New Price Targets

HUMA has been the subject of a number of analyst reports. Benchmark lowered their target price on shares of Humacyte from $17.00 to $14.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. D. Boral Capital reaffirmed a "buy" rating and issued a $25.00 price target on shares of Humacyte in a research note on Tuesday, May 13th. Wall Street Zen raised shares of Humacyte from a "sell" rating to a "hold" rating in a research note on Thursday. Finally, HC Wainwright began coverage on shares of Humacyte in a research note on Wednesday, May 14th. They issued a "buy" rating and a $4.00 price target for the company. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $11.71.

Humacyte Price Performance

Shares of NASDAQ HUMA opened at $2.40 on Friday. The stock has a market capitalization of $372.29 million, a P/E ratio of -1.79 and a beta of 1.64. The company has a 50-day moving average price of $1.78 and a 200-day moving average price of $3.41. Humacyte, Inc. has a 1 year low of $1.15 and a 1 year high of $9.97.

Humacyte (NASDAQ:HUMA - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.09. The firm had revenue of $0.52 million for the quarter, compared to analysts' expectations of $0.46 million. As a group, equities research analysts anticipate that Humacyte, Inc. will post -1.27 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CFO Dale A. Sander purchased 20,000 shares of the business's stock in a transaction that occurred on Thursday, April 10th. The shares were acquired at an average cost of $1.53 per share, for a total transaction of $30,600.00. Following the completion of the acquisition, the chief financial officer now owns 40,600 shares in the company, valued at $62,118. This trade represents a 97.09% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Kathleen Sebelius purchased 50,000 shares of the business's stock in a transaction that occurred on Tuesday, April 8th. The shares were purchased at an average price of $1.32 per share, for a total transaction of $66,000.00. Following the completion of the acquisition, the director now owns 91,207 shares of the company's stock, valued at $120,393.24. The trade was a 121.34% increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 83,993 shares of company stock worth $118,224. 5.10% of the stock is owned by insiders.

Humacyte Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.

Want to see what other hedge funds are holding HUMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humacyte, Inc. (NASDAQ:HUMA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.